Literature DB >> 25642333

State-of-the-art molecular imaging in esophageal cancer management: implications for diagnosis, prognosis, and treatment.

Jolinta Lin1, Seth Kligerman1, Rakhi Goel1, Payam Sajedi1, Mohan Suntharalingam1, Michael D Chuong1.   

Abstract

Molecular imaging techniques are increasingly being used in addition to standard imaging methods such as endoscopic ultrasound (EUS) and computed tomography (CT) for many cancers including those of the esophagus. In this review, we will discuss the utility of the most widely used molecular imaging technique, (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET). (18)F-FDG PET has a variety of potential applications ranging from improving staging accuracy at the time of initial diagnosis to assisting in radiation target volume delineation. Furthermore, (18)F-FDG PET can be used to evaluate treatment response after completion of neoadjuvant therapy or potentially during neoadjuvant therapy. Finally, we will also discuss other novel molecular imaging techniques that have potential to further improve cancer care.

Entities:  

Keywords:  Positron emission tomography (PET); esophageal cancer; molecular imaging; neoadjuvant therapy

Year:  2015        PMID: 25642333      PMCID: PMC4294824          DOI: 10.3978/j.issn.2078-6891.2014.062

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  106 in total

1.  Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy.

Authors:  George W Dittrick; Jill M Weber; Ravi Shridhar; Sarah Hoffe; Marcovalerio Melis; Khaldoun Almhanna; James Barthel; James McLoughlin; Richard C Karl; Kenneth L Meredith
Journal:  Ann Surg Oncol       Date:  2011-11-02       Impact factor: 5.344

2.  Barrett esophagus: New insights into the stem cell organization of Barrett esophagus.

Authors:  Isobel Franks
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-01-31       Impact factor: 46.802

Review 3.  Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy--systematic review.

Authors:  Marinke Westerterp; Henderik L van Westreenen; Johannes B Reitsma; Otto S Hoekstra; Jaap Stoker; Paul Fockens; Pieter L Jager; Berthe L F Van Eck-Smit; John T M Plukker; J Jan B van Lanschot; Gerrit W Sloof
Journal:  Radiology       Date:  2005-09       Impact factor: 11.105

4.  Clinical utility of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the staging of patients with potentially resectable esophageal cancer.

Authors:  John J You; Rebecca K S Wong; Gail Darling; Karen Gulenchyn; Jean-Luc Urbain; William K Evans
Journal:  J Thorac Oncol       Date:  2013-12       Impact factor: 15.609

5.  Comparison of positron emission tomography, computed tomography, and endoscopic ultrasound in the initial staging of patients with esophageal cancer.

Authors:  Val J Lowe; Fargol Booya; J G Fletcher; Mark Nathan; Eric Jensen; Brian Mullan; Eric Rohren; Maurits J Wiersema; Enrique Vazquez-Sequeiros; Joseph A Murray; Mark S Allen; Michael J Levy; Jonathan E Clain
Journal:  Mol Imaging Biol       Date:  2005 Nov-Dec       Impact factor: 3.488

6.  Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.

Authors:  Mark van Heijl; Jikke M Omloo; Mark I van Berge Henegouwen; Otto S Hoekstra; Ronald Boellaard; Patrick M Bossuyt; Olivier R Busch; Hugo W Tilanus; Maarten C Hulshof; Ate van der Gaast; Grard A Nieuwenhuijzen; Han J Bonenkamp; John Th Plukker; Miguel A Cuesta; Fiebo J Ten Kate; Jan Pruim; Herman van Dekken; Jacques J Bergman; Gerrit W Sloof; J Jan van Lanschot
Journal:  Ann Surg       Date:  2011-01       Impact factor: 12.969

7.  Decreased Posttreatment SUV on PET Scan Is Associated With Improved Local Control in Medically Inoperable Esophageal Cancer.

Authors:  Navesh K Sharma; Joshua S Silverman; Tianyu Li; Jonathan Cheng; Jian Q Yu; Oleh Haluszka; Walter Scott; Neal J Meropol; Steven J Cohen; Gary M Freedman; Andre A Konski
Journal:  Gastrointest Cancer Res       Date:  2011-05

Review 8.  Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis.

Authors:  LingLing Pan; Ping Gu; Gang Huang; HuiPing Xue; ShuQi Wu
Journal:  Eur J Gastroenterol Hepatol       Date:  2009-09       Impact factor: 2.566

Review 9.  Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis.

Authors:  F Fiorica; D Di Bona; F Schepis; A Licata; L Shahied; A Venturi; A M Falchi; A Craxì; C Cammà
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

10.  Staging investigations for oesophageal cancer: a meta-analysis.

Authors:  E P M van Vliet; M H Heijenbrok-Kal; M G M Hunink; E J Kuipers; P D Siersema
Journal:  Br J Cancer       Date:  2008-01-22       Impact factor: 7.640

View more
  8 in total

Review 1.  Esophageal cancer: The latest on chemoprevention and state of the art therapies.

Authors:  Gregoire F Le Bras; Muhammad H Farooq; Gary W Falk; Claudia D Andl
Journal:  Pharmacol Res       Date:  2016-08-24       Impact factor: 7.658

2.  Consensus statement of the Hellenic and Cypriot Oesophageal Cancer Study Group on the diagnosis, staging and management of oesophageal cancer.

Authors:  Andreas Fountoulakis; John Souglakos; Louiza Vini; Gerasimos N Douridas; Anna Koumarianou; Panteleimon Kountourakis; Christos Agalianos; Andreas Alexandrou; Christos Dervenis; Sofia Gourtsoyianni; Nikolaos Gouvas; Maria-Angeliki Kalogeridi; Georgia Levidou; Theodoros Liakakos; Joseph Sgouros; Spiros N Sgouros; Charikleia Triantopoulou; Evangelos Xynos
Journal:  Updates Surg       Date:  2019-12-02

3.  Advantages and disadvantages of F-18 fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of unknown primary.

Authors:  Xiaozhou Yu; Xiaofeng Li; Xiuyu Song; Dong Dai; Lei Zhu; Yanjia Zhu; Jian Wang; Huiqin Zhao; Wengui Xu
Journal:  Oncol Lett       Date:  2016-09-29       Impact factor: 2.967

4.  Role of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Newly Found Suspected Malignant Solitary Pulmonary Lesions in Patients Who Have Received Curative Treatment for Colorectal Cancer.

Authors:  Xiaozhou Yu; Xiuyu Song; Lei Zhu; Wei Chen; Dong Dai; Xiaofeng Li; Wengui Xu
Journal:  Gastroenterol Res Pract       Date:  2017-04-12       Impact factor: 2.260

5.  18 Fluorodeoxyglucose-positron emission tomography/computed tomography features of suspected solitary pulmonary lesions in breast cancer patients following previous curative treatment.

Authors:  Lei Zhu; Haiman Bian; Lieming Yang; Jianjing Liu; Wei Chen; Xiaofeng Li; Jian Wang; Xiuyu Song; Dong Dai; Zhaoxiang Ye; Wengui Xu; Xiaozhou Yu
Journal:  Thorac Cancer       Date:  2019-03-21       Impact factor: 3.500

Review 6.  Machine Learning and Radiomics Applications in Esophageal Cancers Using Non-Invasive Imaging Methods-A Critical Review of Literature.

Authors:  Chen-Yi Xie; Chun-Lap Pang; Benjamin Chan; Emily Yuen-Yuen Wong; Qi Dou; Varut Vardhanabhuti
Journal:  Cancers (Basel)       Date:  2021-05-19       Impact factor: 6.639

7.  18F-FDG PET/CT Parameters for Predicting Prognosis in Esophageal Cancer Patients Treated With Concurrent Chemoradiotherapy.

Authors:  Seokmo Lee; Yunseon Choi; Geumju Park; Sunmi Jo; Sun Seong Lee; Jisun Park; Hye-Kyung Shim
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

Review 8.  Modern Management of Esophageal Cancer: Radio-Oncology in Neoadjuvancy, Adjuvancy and Palliation.

Authors:  Francesco Cellini; Stefania Manfrida; Calogero Casà; Angela Romano; Alessandra Arcelli; Alice Zamagni; Viola De Luca; Giuseppe Ferdinando Colloca; Andrea D'Aviero; Lorenzo Fuccio; Valentina Lancellotta; Luca Tagliaferri; Luca Boldrini; Gian Carlo Mattiucci; Maria Antonietta Gambacorta; Alessio Giuseppe Morganti; Vincenzo Valentini
Journal:  Cancers (Basel)       Date:  2022-01-15       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.